The Small Biotech Scaring Big Pharma

It really is the biggest "hidden" opportunity on Wall Street.  Fellow Investor, It really is the [biggest "hidden" opportunity]( on Wall Street. You see, while everyone else has been focused on crypto and pot stocks, we've been focused where no one else was looking: the biotech sector. As a result, we've had a different biotech stock taken over every 56 days... I'm truly grateful to be able to share my passion for biotech stocks with you (and I hope you've made some good money!). But today, I thought I'd take a moment to discuss where this [big merger wave]( is coming from. It all started back in 1990 with the Human Genome Project (HGP), the international scientific research project dedicated to mapping the human genome. One of the many big benefits of the HGP was that for the first time ever, scientists were able to identify mutations linked to different forms of cancer. It wasn't long before they began to design new medications to address them. Now here's where it gets interesting... 75% of Cancer Drugs are Old Chemical Drugs Currently, 75% of all drugs to treat cancer are old chemical drugs. For example, the most popular drug to treat Leukemia is Cytarbine. Well guess what? Cytarbine was patented in 1960! A lot has changed in medicine since 1960! That's why the side effects are horrendous. They include bone marrow suppression, vomiting, diarrhea, liver problems, rash, ulcer formation in the mouth, and bleeding. Many of you know first-hand what I'm talking about. Going through chemo yourself or watching a loved one go through it is brutal. Absolutely brutal. This is what they mean by the expression "the chemo will get you before the cancer does." The good news is that that's now the "OLD WAY" of fighting cancer. Ever since the HGP, scientists have begun to develop molecular profiles of both the patient and the actual cancer. And they've been creating treatments based on those profiles. Precision-medicine. Now we have a whole "NEW WAY" of fighting cancer. [Find out the Small Biotech scaring Big Pharma ]( How does that make this such a golden opportunity for takeover investors? It's simple... Worldwide spending on cancer therapies was about $140 billion in 2018, according to the American Association of Cancer Research. $105 billion, or 75% of that money was spent on the "OLD WAY" of treating cancer. $35 billion, or 25%, was spent on the "NEW WAY" of treating cancer. Well guess what? Those numbers are about to flip. It won't be long before 75% of all money for cancer therapies are spent on the "NEW WAY" of fighting cancer. It gets even better... Right now, Big Pharma (Pfizer, Eli Lilly, Glaxo, Bristol Meyers, etc) owns the "OLD WAY" oncology market. They have it locked down. But a new crop of small biotech companies is developing the "NEW WAY" oncology market. The Small Biotech Scaring Bristol Meyers One tiny biotech invented a breakthrough Leukemia treatment. This new medicine targets patients by their genetic profile. This new discovery threatens Big Pharma companies Bristol Meyers and Novartis. That makes this small biotech our top takeover target this month. [Find out the rest of the story here ]( And guess what? Big Pharma has to buy Small Pharma if they want to keep their place in the market. That's why we've been able to rack up such great gains riding this wave - Pfizer bought "NEW WAY" firm Array Biopharma last month for $48 a share, a 144% gain from our recommended price of $18.90. Glaxo bought "NEW WAY" firm Tesaro in March for $74.96, a 93% gain from our recommended price of $38.41. Eli Lilly bought "NEW WAY" firm Loxo Oncology in January for $234.66, a 78% gain from our recommended price of $131.02. Illumina bought "NEW WAY" diagnostic firm Pacific Biosciences for $8, an 82% gain from our recommended price of $4.38. Want to know the next "NEW WAY" cancer drug company we think gets acquired? [Find out the Small Biotech scaring Big Pharma ](  "The Buck Stops Here" [Click Here]( Dylan J. Chairman, Behind the Markets If you are you having trouble receiving your IncomeInsider.net subscription, you can ensure its arrival in your mailbox by [whitelisting IncomeInsider.net and insiders@incomeinsider.net](. IncomeInsider.net (collectively, the “Company” or “we” used herein) bears no responsibility or control over the content of the sponsored content and/or the product or service offered. Compensation Disclaimer The Company is a publisher that publishes impersonal views which are not adapted to any specific person, portfolio or need. You understand that no content published as part of the information provided herein constitutes a recommendation that any product, service, particular investment, security, portfolio of securities, transaction or investment strategy is suitable for any specific person. You further understand that none of the creators, providers or publishers of the information contained in this sponsored content, or their affiliates, will advise you personally concerning the nature, potential, value or suitability of the product, service, any particular investment, security, portfolio of securities, transaction, investment strategy or other matter. The information herein is provided and should be considered only for general informational purposes only and should not be considered or relied upon as investment advisory. The Company is a publisher only, and is not a securities broker or dealer, nor is the Company an investment advisor. To the extent that any of the information published as part of this sponsored content may be deemed to be investment advisory, such information is general and impersonal and not tailored to the investment needs of any specific person. There is a very high degree of risk involved in trading securities. Past results are not indicative of future returns. The Company and all individuals affiliated with this site assume no responsibilities for your trading and investment results. The views published in this sponsored content are for educational purposes only and should not be construed as investment advisory. The information contained in this sponsored content, including any observations depicted herein, is obtained from sources believed to be reliable, but the Company does not warrant and there is no guarantee of its completeness or accuracy. Any information expressed herein is based upon interpretations of the information from sources outside of the Company. The Company has not verified the truthfulness of the information.  There is no warranty or guarantee of any results, outcome or profit from your use of the information expressed herein. We and our affiliates are not under any obligation to update or correct any information provided on this website. All statements in this sponsored content are subject to change without notice. Your use of the information is entirely at your own risk and it is your sole responsibility to evaluate the accuracy, completeness and usefulness of the information. Past performance is not indicative of future results. You should be aware of the real risk of loss in following any views discussed on this website or in the Company’s emails.  The views discussed may change as products fluctuate in price or value, and we will not update you on any change in the views published. Investors may get back less than invested. Views mentioned on this website or the Company’s emails may not be suitable for you. The material in this sponsored content does not take into account your particular investment objectives, financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding views mentioned on this website or emails. Before acting on information on this website or emails, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser. You must assess the risk of any trade with your advisor and make your own independent decisions regarding any information mentioned herein. The information contained herein is not furnished in connection with a sale or offer to sell securities or in connection with the solicitation of an offer to buy securities. Our Company, including our affiliates, may have a position or effect transactions in the securities described herein (or options thereon) and may make purchases or sales of these securities while this sponsored content is in circulation. We also may employ trading strategies that may be consistent or inconsistent with the strategies provided or discussed herein.  IncomeInsider.net Disclaimer This is a paid sponsored content, Claims have not been independently verified. All of the content on our website and in our emails is for informational and illustrative purposes only, and should not be construed as an offer, or solicitation of an offer to buy or sell securities. You should always consult with a licensed securities professional before purchasing or selling securities.. Any results where shown are strictly hypothetical, and were executed in simulated trading accounts. CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN. Earnings Disclaimer: Our website, blogs and emails use affiliate and sponsorship programs for monetization, which means when you click on ads or links, this can result in a commission that is credited to our company.  Compliance: All header and reply-to information is accurate; you may reply directly to this email or send your reply to the physical address or email listed below. Subject lines reflect the content of the email and the email is clearly identified as an sponsored content. All opt-outs are automatically honored and managed by the system. IncomeInsider.net has been retained by a third party to perform promotional and marketing services for a limited time with respect to the company we are profiling or discussing on this website or in this email. In exchange for such services IncomeInsider.nethas received or will receive cash compensation from the third party. Questions regarding this may be sent to insiders@incomeinsider.net  Generally, the information regarding a company profiled or discussed on this website or email is provided from public sources. IncomeInsider.net makes no representations, warranties or guarantees as to the accuracy or completeness of the information provided or discussed. In the event that a particular stock is being reviewed, it is important to note IncomeInsider.net, its principles and employees do not trade on this information.  Subscriber Id: c35b5090289a030d5f71723db89dd233 [Click here if you are not human](  Proudly brought to you by: IncomeInsider.net, 16-58 Marsh Wall, E149TP London UK In order to unsubscribe from this mailing list, please click [here](